In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- Paragangliomas

Last updated: December 20, 2021
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neuroendocrine Carcinoma

Treatment

N/A

Clinical Study ID

NCT04583384
APHP200281
2020-A00397-32
  • Ages > 18
  • All Genders

Study Summary

Qualitative and quantitative biomarker of response to radiotherapy is needed in paragangliomas. We aim at assessing the added value of 1H-SRM for the evaluation of early response to EBR therapy in patients with cervical SDHx PGL.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years
  • Signed informed consent
  • Patient with cervical PGL with planning of treatment with EBR
  • Patient with an SDHx mutation or unknown genetic status
  • Patient affiliated to a social security scheme

Exclusion

Exclusion Criteria:

  • Pregnant woman
  • Contraindication to MRI (implantable device, etc.)
  • Impossibility of lying down without movement for 45 minutes (hyperalgesic patient,claustrophobia, etc.)
  • PPGL having previously been the subject of local (excluding surgery) or systemictreatment
  • PPGL <1 cm longest axis
  • Patient under guardianship or curatorship

Study Design

Total Participants: 32
Study Start date:
October 27, 2020
Estimated Completion Date:
June 30, 2025

Study Description

Paragangliomas (PGL) are rare neuroendocrine tumors inherited in 40% of cases. SDHx genes (SDHA, SDHB, SDHC, SDHD), encoding the 4 subunits of the mitochondrial enzyme succinate dehydrogenase (SDH), are the most frequently involved.

Accumulation of succinate, the substrate for SDH, is a very specific biomarker for these mutations. Recently, we have demonstrated the feasability of detecting and quantifying succinate in tumors in vivo, by magnetic resonance spectroscopy (1H-SRM).

Patients carrying these mutations frequently develop cervical PGL for which the treatment of choice is external beam radiation therapy (EBR).

The objective of this project is to determine the feasibility of using 1H-SRM for the evaluation of early response to EBR therapy in patients with cervical SDHx PGL.

Connect with a study center

  • Hopital européen Georges Pompidou

    Paris, 75015
    France

    Active - Recruiting

  • Hôpital Lariboisière

    Paris, 75010
    France

    Active - Recruiting

  • Hôpital Pitié-Salpêtrière

    Paris, 75013
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.